Recombinant BCG Overexpressing a STING Agonist Elicits Trained Immunity and Improved Antitumor Efficacy in Non-Muscle Invasive Bladder

doi 10.1101/2020.04.25.061531
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Cold Spring Harbor Laboratory

Related search

Compared Efficacy of Intravesical BCG vs Mitomycin-C, and Other Dual Therapies in Non-Muscle Invasive Bladder Cancer

Cancer therapy & Oncology International Journal
2018English

IL-9 BCG Immunotherapy for Non-Muscle Invasive Bladder Cancer in Europe

Japanese Journal of Urology
Urology
2007English

A Developed STING Agonist Has Systemic Antitumor Activity

Cancer Discovery
Oncology
2018English

Lba27 Phase 3 Study of Vicinium in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer: Initial Results

Journal of Urology
Urology
2018English

Mp65-17 Intravesical Thalidomide Boosts Bacillus Calmete-Guérin (Bcg) in Non-Muscle Invasive Bladder Cancer Treatment

Journal of Urology
Urology
2017English

Does 5-Alpha Reductase Inhibitor Use Improve the Efficacy of Intravesical Bacille Calmette-Guérin (BCG) for Non-Muscle Invasive Bladder Cancer?

Bladder Cancer
OncologyUrology
2020English

Collagen Stiffness Promoted Non-Muscle-Invasive Bladder Cancer Progression to Muscle-Invasive Bladder Cancer

OncoTargets and Therapy
OncologyPharmacology
2019English

Prediction Tools in Non-Muscle Invasive Bladder Cancer

Translational Andrology and Urology
Reproductive MedicineUrology
2019English

Histological Variants in Non-Muscle Invasive Bladder Cancer

Translational Andrology and Urology
Reproductive MedicineUrology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy